%0 Journal Article
%T Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
%A Angelo Avogaro
%A Benedetta Maria Bonora
%A Elisabetta Iori
%A Gian Paolo Fadini
%A Giancarlo Zatti
%A Maria Cristina Marescotti
%A Mattia Albiero
%A Nicola Vitturi
%J Archive of "Cardiovascular Diabetology".
%D 2017
%R 10.1186/s12933-017-0529-3
%X Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin affects HDL function in a randomized placebo-controlled trial
%K Atherosclerosis
%K Body composition
%K Therapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379610/